Nastech Shows In Vivo Data on Arthritis Drug, Sees RNAi s Knock Down as Key Selling Point | GenomeWeb

RNAi newcomer Nastech released last week the first in vivo data on its experimental siRNA-based rheumatoid arthritis treatment to come out of its partnership with the Mayo Clinic.

The data, presented at the American College of Rheumatology's annual scientific meeting in San Diego, indicate that the company's RNAi drug is able to stop the production of human TNF-alpha in mouse models of the disease. TNF-alpha is a protein that is over-expressed in certain inflammatory disorders including rheumatoid arthritis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.